Medicare Coverage and the Utilization of Comprehensive Genomic Profiling in Advanced Cancer Cases

Overview

This study examines the utilization of broad genomic profiling (BGP) among Medicare beneficiaries with metastatic cancer, highlighting differences in usage based on payer type and geographic region. Despite national guidelines recommending BGP, its use remains suboptimal, influenced by various systemic barriers.

Background

Broad genomic profiling is increasingly recognized as essential for guiding treatment decisions in advanced cancer. National guidelines advocate for its use in metastatic cancer cases, yet disparities in access and utilization persist, particularly influenced by payer policies and regional healthcare structures. Understanding these barriers is crucial for improving cancer care quality and ensuring equitable access to precision oncology.

Data Highlights

No numerical data provided in the article.

Key Findings

• BGP use has increased but remains underutilized among Medicare beneficiaries.
• Medicare Advantage (MA) plans may impose barriers to high-quality cancer care compared to fee-for-service (FFS) plans.
• Geographic variation significantly affects BGP utilization, with differences observed across hospital referral regions.
• MA plans are associated with delayed treatment initiation and reduced survival in metastatic lung cancer patients.
• Variability in cost-containment strategies among MA plans impacts access to guideline-concordant genomic testing.

Clinical Implications

Healthcare providers should be aware of the differences in BGP utilization based on payer type and geographic location. Addressing systemic barriers is essential to enhance access to genomic testing and improve patient outcomes in advanced cancer care.

Conclusion

The study underscores the need for a deeper understanding of the factors influencing BGP utilization among Medicare beneficiaries to promote equitable access to precision oncology.

Related Resources & Content

1. The ASCO Post, August 15, 2013 -- Molecular Tests and Precision Medicine: Not So Fast Now!
2. The ASCO Post, April 2025 -- Medicare Claim Denials for Cancer-Related NGS Testing Show Uncertainty of Coverage
3. The ASCO Post, September 1, 2013 -- Integrating Genomic Sequencing Into Clinical Care
4. The ASCO Post, July 2025 -- Biomarker Testing in Advanced Cancer: Suboptimal Rates Despite Guideline Recommendations and Growing Insurance Coverage
5. NCD - Next Generation Sequencing (NGS) (90.2)
6. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology
7. Adoption of Broad Genomic Profiling in Patients With Cancer | Genetics and Genomics | JAMA Oncology | JAMA Network
8. NCD - Next Generation Sequencing (NGS) (90.2)
9. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology
10. Adoption of Broad Genomic Profiling in Patients With Cancer | Genetics and Genomics | JAMA Oncology | JAMA Network